SOURCE: AtCor Medical Holdings Ltd.

AtCor Medical Holdings Ltd.

July 08, 2010 14:33 ET

AtCor Medical Announces New $1.77 Million Pharmaceutical Clinical Trials Contract

Over $2.9 Million in New Pharma Contracts in the Past Three Months

ITASCA, IL--(Marketwire - July 8, 2010) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The $1.77 million contract is with an existing AtCor customer.

Duncan Ross, AtCor Medical CEO, said, "AtCor has closed new contracts valued at $2.9 million since March, demonstrating the resurgence of the pharmaceutical clinical trial sector since the US healthcare reform legislation was signed. This significant contract confirms AtCor's market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows that AtCor's reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients."

Mr. Ross added, "Scientific publications continue to reinforce the importance of using central blood pressure as a measurement. This mounting body of evidence helps to drive our sales in the pharmaceutical clinical trials market and supports the accelerated adoption of SphygmoCor in clinical practice. Understanding a drug's effect on central pressure is vitally important in assessing efficacy and assuring drug safety in clinical trials. It is equally important in patient care."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure noninvasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical centers, research institutions, in leading physician practices and in pharmaceutical clinical trials. The company's technology has been featured in hundreds of studies published in leading peer-reviewed medical journals. AtCor has operations in Australia, the United States and Europe. For further information, please visit our web site at

Contact Information

  • For further information, please contact:

    Duncan Ross
    AtCor Medical

    Larry Watts
    AtCor Medical
    Director, Marketing Services